# Lu AE58054 Added to Donepezil for the Treatment for Moderate Alzheimer's Disease

> **NCT01019421** · PHASE2 · COMPLETED · sponsor: **H. Lundbeck A/S** · enrollment: 278 (actual)

## Conditions studied

- Alzheimer's Disease

## Interventions

- **DRUG:** Lu AE58054
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01019421
- **Lead sponsor:** H. Lundbeck A/S
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-12
- **Primary completion:** 2011-12
- **Final completion:** —
- **Target enrollment:** 278 (ACTUAL)
- **Last updated:** 2012-01-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01019421

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01019421, "Lu AE58054 Added to Donepezil for the Treatment for Moderate Alzheimer's Disease". Retrieved via AI Analytics 2026-06-30 from https://api.ai-analytics.org/clinical/NCT01019421. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*